Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study With COmbination of Vemurafenib With Cobimetinib in B-RAF V600E/K Mutated Melanoma Patients to Normalize LDH and Optimize Nivolumab and Ipilimumab therapY

NCT02968303 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT02968303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02968303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study With COmbination of Vemurafenib With Cobimetinib in B-RAF V600E/K Mutated Melanoma Patients to Normalize LDH and Optimize Nivolumab and Ipilimumab therapY
Lead sponsor
Radboud University Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
January 27, 2017
Completion date
October 31, 2023
Enrollment
200 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, malignant, of soft parts